The value of serum free light chain assay in patients with monoclonal gammopathies and renal failure
Valor del ensayo de las cadenas ligeras libres en suero para los pacientes de gammapatías monoclonales e insuficiencia renal
Read
17277
Timeswas read the article
3504
Total PDF
13773
Total HTML
Share statistics
array:21 [ "pii" => "X2013251412000601" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2011.Nov.11098" "estado" => "S300" "fechaPublicacion" => "2012-01-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2012;32:15-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 9531 "formatos" => array:3 [ "EPUB" => 309 "HTML" => 8324 "PDF" => 898 ] ] "Traduccion" => array:1 [ "es" => array:17 [ "pii" => "X0211699512000604" "issn" => "02116995" "doi" => "10.3265/Nefrologia.pre2011.Nov.11098" "estado" => "S300" "fechaPublicacion" => "2012-01-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2012;32:15-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 21483 "formatos" => array:3 [ "EPUB" => 309 "HTML" => 20046 "PDF" => 1128 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Valor del ensayo de las cadenas ligeras libres en suero para los pacientes de gammapatías monoclonales e insuficiencia renal" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "15" "paginaFinal" => "19" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "The value of serum free light chain assay in patients with monoclonal gammopathies and renal failure" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11098_108_19760_es_11098_f1.jpg" "Alto" => 398 "Ancho" => 600 "Tamanyo" => 286192 ] ] "descripcion" => array:1 [ "es" => "Cadenas ligeras libres y el riñón" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M. Luisa Campos, Nuno M. Barbosa-de Carvalho, Guillermo Martín-Reyes" "autores" => array:3 [ 0 => array:2 [ "nombre" => "M. Luisa" "apellidos" => "Campos" ] 1 => array:2 [ "nombre" => "Nuno M." "apellidos" => "Barbosa-de Carvalho" ] 2 => array:2 [ "nombre" => "Guillermo" "apellidos" => "Martín-Reyes" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "X2013251412000601" "doi" => "10.3265/Nefrologia.pre2011.Nov.11098" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412000601?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512000604?idApp=UINPBA000064" "url" => "/02116995/0000003200000001/v0_201502091357/X0211699512000604/v0_201502091357/es/main.assets" ] ] "itemSiguiente" => array:17 [ "pii" => "X2013251412000589" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2011.Nov.11065" "estado" => "S300" "fechaPublicacion" => "2012-01-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2012;32:20-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 8821 "formatos" => array:3 [ "EPUB" => 341 "HTML" => 7592 "PDF" => 888 ] ] "en" => array:12 [ "idiomaDefecto" => true "titulo" => "Renal supportive care and palliative care: revision and proposal in kidney replacement therapy" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "20" "paginaFinal" => "27" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Cuidados de soporte renal y cuidados paliativos renales: revisión y propuesta en terapia renal sustitutiva" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11065_16025_25899_en_t1_11065.jpg" "Alto" => 1042 "Ancho" => 1080 "Tamanyo" => 1052674 ] ] "descripcion" => array:1 [ "en" => "The four principles of modern bioethics" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "JUAN PABLO LEIVA-SANTOS, Juan P. Leiva-Santos, ROSA SANCHEZ HERNANDEZ, Rosa Sánchez-Hernández, HELENA GARCÍA-LLANA, Helena García-Llana, MARÍA JOSÉ FERNÁNDEZ-REYES, M. José Fernández-Reyes, MANUEL HERAS BENITO, Manuel Heras-Benito, ÁLVARO Molina Ordas, Álvaro Molina-Ordas, ASTRID Rodríguez, Astrid Rodríguez, FERNANDO Álvarez-Ude, Fernando Álvarez-Ude" "autores" => array:16 [ 0 => array:2 [ "nombre" => "JUAN PABLO" "apellidos" => "LEIVA-SANTOS" ] 1 => array:2 [ "nombre" => "Juan P." "apellidos" => "Leiva-Santos" ] 2 => array:2 [ "nombre" => "ROSA" "apellidos" => "SANCHEZ HERNANDEZ" ] 3 => array:2 [ "nombre" => "Rosa" "apellidos" => "Sánchez-Hernández" ] 4 => array:2 [ "nombre" => "HELENA" "apellidos" => "GARCÍA-LLANA" ] 5 => array:2 [ "nombre" => "Helena" "apellidos" => "García-Llana" ] 6 => array:2 [ "nombre" => "MARÍA JOSÉ" "apellidos" => "FERNÁNDEZ-REYES" ] 7 => array:2 [ "nombre" => "M. José" "apellidos" => "Fernández-Reyes" ] 8 => array:2 [ "nombre" => "MANUEL" "apellidos" => "HERAS BENITO" ] 9 => array:2 [ "nombre" => "Manuel" "apellidos" => "Heras-Benito" ] 10 => array:2 [ "nombre" => "ÁLVARO" "apellidos" => "Molina Ordas" ] 11 => array:2 [ "nombre" => "Álvaro" "apellidos" => "Molina-Ordas" ] 12 => array:2 [ "nombre" => "ASTRID" "apellidos" => "Rodríguez" ] 13 => array:2 [ "nombre" => "Astrid" "apellidos" => "Rodríguez" ] 14 => array:2 [ "nombre" => "FERNANDO" "apellidos" => "Álvarez-Ude" ] 15 => array:2 [ "nombre" => "Fernando" "apellidos" => "Álvarez-Ude" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699512000581" "doi" => "10.3265/Nefrologia.pre2011.Nov.11065" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512000581?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412000589?idApp=UINPBA000064" "url" => "/20132514/0000003200000001/v0_201502091620/X2013251412000589/v0_201502091620/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "X201325141200061X" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2011.Nov.11167" "estado" => "S300" "fechaPublicacion" => "2012-01-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2012;32:12-4" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 5983 "formatos" => array:3 [ "EPUB" => 334 "HTML" => 4874 "PDF" => 775 ] ] "en" => array:9 [ "idiomaDefecto" => true "titulo" => "Longitudinal observational studies and causality" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "12" "paginaFinal" => "14" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Estudios observacionales longitudinales y causalidad" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Alfonso Muriel, Domingo Hernández-Marrero, Víctor Abraira" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Alfonso" "apellidos" => "Muriel" ] 1 => array:2 [ "nombre" => "Domingo" "apellidos" => "Hernández-Marrero" ] 2 => array:2 [ "nombre" => "Víctor" "apellidos" => "Abraira" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699512000612" "doi" => "10.3265/Nefrologia.pre2011.Nov.11167" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512000612?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X201325141200061X?idApp=UINPBA000064" "url" => "/20132514/0000003200000001/v0_201502091620/X201325141200061X/v0_201502091620/en/main.assets" ] "en" => array:12 [ "idiomaDefecto" => true "titulo" => "The value of serum free light chain assay in patients with monoclonal gammopathies and renal failure" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "15" "paginaFinal" => "19" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "M. Luisa Campos, Nuno M. Barbosa-de Carvalho, Guillermo Martín-Reyes" "autores" => array:3 [ 0 => array:4 [ "nombre" => "M. Luisa" "apellidos" => "Campos" "email" => array:1 [ 0 => "luisa.campos@bindingsite.es" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 1 => array:3 [ "nombre" => "Nuno M." "apellidos" => "Barbosa-de Carvalho" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 2 => array:3 [ "nombre" => "Guillermo" "apellidos" => "Martín-Reyes" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => " The Binding Site Spain, Barcelona, " "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] 1 => array:3 [ "entidad" => " Hospital Regional Universitario Carlos Haya, Málaga, " "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Valor del ensayo de las cadenas ligeras libres en suero para los pacientes de gammapatías monoclonales e insuficiencia renal" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11098_16025_25688_en_f1_11098.jpg" "Alto" => 1311 "Ancho" => 2089 "Tamanyo" => 1893534 ] ] "descripcion" => array:1 [ "en" => "Free light chains and the kidney" ] ] ] "textoCompleto" => "<p class="elsevierStylePara">Monoclonal gammopathies (MG) are blood dyscrasias that result from a neoplastic process in plasma cell (PC) clones, and are usually associated with an elevated production of a monoclonal protein (MP). This paraprotein can be an intact immunoglobulin or a light chain (LC). The immunoglobulins are composed of an identical pair of heavy chains joined to two identical kappa (κ) or lambda (λ) LC. The heavy and light chains are produced separately, and are later joined and secreted into the bloodstream. In order to ensure correct conformation of the immunoglobulins, PC produce an excess of LC, whose surplus is secreted along with the com­pleted immunoglobulins. In this manner, 40% of LC are found free in the serum, not joined to heavy chains.<span class="elsevierStyleSup">1 </span>These serum free light chains (sFLC) have a different conformation: κFLC present as 25kDa monomers, whereas λFLC form 50kDa dimers. </p><p class="elsevierStylePara"><span class="elsevierStyleBold">DIAGNOSING MONOCLONAL GAMMOPATHIES </span></p><p class="elsevierStylePara">The diagnosis of MG is based on detecting the circulating paraprotein. Serum protein electrophoresis (SPE) is the most commonly used technique for measuring monoclonal bands, but its sensitivity is limited: it is incapable of detecting MP at concentrations <400mg/l, levels that are frequently observed in cases of Bence-Jones (BJ) or light chain multiple myeloma (BJMM).<span class="elsevierStyleSup">2 </span>Immunofixation electrophoresis (IFE) is a more sensitive technique for characterising the type of MP but not to quantify it, and therefore it is of limited application during the MG follow-up. Both urine electrophoresis and immunofixation are more sensitive than their equivalents in serum samples<span class="elsevierStyleSup">1,4</span>; however, they are affected by the renal function of the patient, which is their primary disadvantage (Figure 1). Nephelometric techniques are the most precise and sensitive analytical methods available, but they do not make the distinction between monoclonal and polyclonal backgroud. A recent addition to the last techniques has been the sFLC assay, which allows for measuring sFLC and determining monoclonality by establishing the ratio of κvs λsFLC.<span class="elsevierStyleSup">2 </span>This assay allows the detection of κFLC and λFLC separately using polyclonal antibodies produced in sheep that specifically recognise epitopes in the constant region of LC that are hidden in intact immunoglobulins, but are exposed in sFLC.<span class="elsevierStyleSup">1 </span>The sFLC assay is the most sensitive assessment technique currently available. However, no technique can provide by itself a diagnosis of the various types of MG, and so they must be used together in order to provide a high sensitivity in the diagnosis.<span class="elsevierStyleSup">5 </span></p><p class="elsevierStylePara">For the first time, sFLC assay allowed for measuring normal serum levels and determining a reference range for normal subjects. The normal range of κFLC is 3.3-19.4mg/l, and the normal range for λFLC is 5.7-26.3mg/l, with a normal interval for the κ/λsFLC of 0.26-1.65.<span class="elsevierStyleSup">6 </span>Using this range in a retrospective study, Bradwell demonstrated that 100% of patients with BJMM have an altered κ/λratio, suggesting monoclonality.<span class="elsevierStyleSup">7 </span>In the field of MG, sFLC assay has shown a greater sensitivity for detecting the monoclonal component, with special relevance in non-secretory MM, in which it is now possible to measure and monitor MP without having to recurre to invasive techniques, and in the case of AL amyloidosis, where international guidelines recommend measuring sFLC as part of the diagnostic process.<span class="elsevierStyleSup">8,9 </span>Additionally, measuring sFLC at the moment of diagnosing MM and other MG takes on a role in prognosis and will provide a valuable baseline value for monitoring the patient during treatment.<span class="elsevierStyleSup">8,10 </span>Recently, Katzmann performed a study with 1877 patients with MG, showing that a higher sensitivity for diagnosis could be achieved for the majority of malignant MG using a protocol of serum analyses (SPE + sFLC + sIFE). Based on their results, these authors proposed replacing IFE in 24-hour urine samples with the sFLC assay.<span class="elsevierStyleSup">11 </span>This simple algorithm allows for orientating the diagnosis towards cast nephropathy (Figure 2). In a similar manner, the International Myeloma Working Group recommended using a combination of SPE, sFLC, and sIFE for tracking MG, and suggested that the sFLC assay could substitute IFE in 24-hour urine samples. This last test, however, still remains necessary in the case of strong, unconfirmed suspicion of AL amyloidosis.<span class="elsevierStyleSup">8 </span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">RENAL FAILURE AND THE NEW RANGE OF NORMALITY FOR PATIENTS WITH A PRIOR ABNORMAL RENAL FUNCTION </span></p><p class="elsevierStylePara">One important consideration for clinical practice is that the renal failure itself affects sFLC levels due to the reduced filtration rate. However, the sFLC assay has shown that, in the majority of cases of renal failure not derived from MG, the sFLC coefficient remains within its normal range. Some patients with renal failure have values that fall just outside of the normal range. This abnormal value in the κ/λcoefficient is proportional to the progression of the renal disease, and can pose a challenge when diagnosing patients with renal failure prior to MG.<span class="elsevierStyleSup">12,13 </span>In order to avoid this issue, Hutchison measured κ and λ sFLC in 688 patients with renal failure and no MG, establishing a new range of normality for patients with renal failure at 0.37-3.1.<span class="elsevierStyleSup">12,13 </span>The new “renal range” has been validated, and maintains a sensitivity of 100%, improving the specificity for the assay in cases of renal failure from 93% to 99%.<span class="elsevierStyleSup">13,14 </span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">NEPHROTOXIC PROPERTIES OF SERUM FREE LIGHT CHAINS </span></p><p class="elsevierStylePara">MG are frequently associated with renal disease, and up to 50% of patients with MM already have altered renal function at the time of diagnosis (10%-20% dependent on dialysis).<span class="elsevierStyleSup">15,16 </span>The nephrotoxic properties of sFLC are well known, and are attributed with the increased risk of suffering renal damage in patients with MG. Their toxicity can develop at different levels: 1) glomerular: formation of amyloid fibrils, usually λsFLC, or deposits in the basal membrane associated with κsFLC; 2) proximal tubule: the exacerbated process of reabsorption stimulates the production of cytokines and, consequently, the inflammatory response and fibrosis produced can lead to acute tubular necrosis; or, even, by the incapacity of cells to degrade FLC that accumulate intracellularly, forming crystals characteristic of Fanconi syndrome<span class="elsevierStyleSup">17</span>; 3) the distal tubule: once the absorption capacity of the proximal tubule is surpassed, the FLC precipitate with Tamm-Horsfall proteins, causing cast nephropathy with the formation of waxy casts that eventually block the nephron and produce renal failure (Figure 1). Cast nephropathy, or “myeloma kidney,” is the most commonly seen nephropathy in MM. This condition is irreversible as long as the tumour remains active, and is associated with a worse prognosis, making effective tools for an early diagnosis essential, so as to detect MG before the appearance of this renal lesions.<span class="elsevierStyleSup">18 </span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">IMPACT OF AN EARLY DIAGNOSIS </span></p><p class="elsevierStylePara">The amount of time elapsed before a diagnosis is established and treatment is started is very important. A prolonged time until MM is diagnosed increases the probability of complications, among which stands out renal lesions.<span class="elsevierStyleSup">19,20 </span>The nephrologist plays a central role in the early diagnosis of the disease as a substantial portion of patients develop acute renal failure without known MG.<span class="elsevierStyleSup">21 </span>Particularly in relation to myeloma kidney, 50% of patients will seek treatment in the nephrology department, 100% of which are identifiable using sFLC assays.<span class="elsevierStyleSup">13,22 </span>Recent studies have shown that a rapid decrease in sFLC allows for a greater rate of renal recovery. This is due to the progression of the disease towards interstitial fibrosis, which results in irreversible renal damage.<span class="elsevierStyleSup">20 </span>Once more, the delay before clinical intervention will determine the prognosis, since 80% of patients require a reduction in sFLC >60% by day 21 in order to reach renal recovery, and this renal recovery entails a significant improvement in survival.<span class="elsevierStyleSup">23 </span></p><p class="elsevierStylePara">A rapid diagnosis and start of treatment are possible through good interaction between nephrologists, haematologists, and oncologists, leading to improved survival. Given the high sensitivity of the test, sFLC measurement allows for a rapid identification of nephrotoxic monoclonal proteins in patients with acute renal failure.<span class="elsevierStyleSup">23 </span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">MONITORING TREATMENT </span></p><p class="elsevierStylePara">In addition to providing a tool for the early diagnosis of MG, sFLC assay plays an important role in monitoring the elimination of sFLC in patients with MG. The strategy for treating MM is based on the application of chemotherapy to eliminate the malignant PC clone, and at the same time, direct elimination of the circulating sFLC in the bloodstream. </p><p class="elsevierStylePara">The treatment of MM has evolved substantially in recent years due to the development of more effective and faster drugs, such as thalidomide, lenalidomide, and bortezomib, with higher response rates and better long-term results. Bortezomib is approved by the FDA, is well-tolerated by patients with renal failure, and its pharmacokinetics is not affected by the level of renal failure, so it can be administered with no need for readjusting the dose. Bortezomib with dexamethasone is the recommended treatment for patients with MM and renal failure of any level.<span class="elsevierStyleSup">24 </span></p><p class="elsevierStylePara">Plasmapheresis has not shown to be as effective as expected for eliminating sFLC.<span class="elsevierStyleSup">25,26 </span>The fact that a large part of the circulating sFLC are located in the extravascular space, along with limits to the duration and frequency of plasmapheresis cycles, may be the basis for the lack of effectiveness observed with this treatment. However, the studies performed until now have supported the relationship between a reduction in sFLC levels and renal recovery.<span class="elsevierStyleSup">21,26 </span>More recently, different haemodialysis filters have been developed with a high cut-off point (HCO), which allows for the passage of sFLC without an excessive loss of albumin.<span class="elsevierStyleSup">16,27 </span>The HCO 1100 membrane has demonstrated its high effectiveness that, in combination with proper chemotherapy, produces promising results for the recovery of patients with myeloma kidney.<span class="elsevierStyleSup">28,29 </span>A swift and constant decrease in sFLC was associated with recovery of the kidney in 74% of patients in the study by Hutchison,<span class="elsevierStyleSup">28 </span>and 50% in the study published by Martin-Reyes<span class="elsevierStyleSup">29 </span>in this same issue of Nefrología. Given the short half-life of sFLC in comparison to intact immunoglobulins, measuring sFLC allows for determining levels before and after each cycle of haemodialysis almost in real time.<span class="elsevierStyleSup">29 </span>In this manner, measuring sFLC is important in monitoring the treatment of these patients because it allows us to: 1) evaluate the efficient elimination of sFLC during dialysis; 2) analyse the efficiency of chemotherapy during treatment, with the option of adjusting the treatment regimen as needed; 3) determine the moment in which the patient has recovered renal function, starting to metabolise the sFLC anew; and 4) early diagnosis of recurrence. </p><p class="elsevierStylePara">Each year, the incidence of MM increases, but we have the possibility of providing more effective treatment to these patients. This is due to the development of more effective new-generation chemotherapies, in addition to the possibility of offering a rapid decrease in circulating sFLC, thus reducing the probability of irreversible renal damage, which reduces survival.<span class="elsevierStyleSup">30 </span>As such, this is an important time of great advancements and expectations in the treatment of MM and the recovery of these patients, in which the clinician still plays an important role in providing attentive care and quick action. However, no therapy provides effective results after a late diagnosis, and the major advantage that we have today is a simple protocol that allows us to identify patients with clinically relevant MG efficiently and earlier. </p><p class="elsevierStylePara"><span class="elsevierStyleBold">Conflicts of interest </span></p><p class="elsevierStylePara">The authors M. Luisa Campos and Nuno M. Barbosa de Carvalho work for Binding Site Spain. </p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><a href="grande/11098_16025_25688_en_f1_11098.jpg" class="elsevierStyleCrossRefs"><img src="11098_16025_25688_en_f1_11098.jpg" alt="Free light chains and the kidney"></img></a></p><p class="elsevierStylePara">Figure 1. Free light chains and the kidney</p><p class="elsevierStylePara"><a href="grande/11098_16025_25689_en_f2_11098.jpg" class="elsevierStyleCrossRefs"><img src="11098_16025_25689_en_f2_11098.jpg" alt="Proposed protocol for the diagnosis and follow-up of acute renal failure/monoclonal gammopathy"></img></a></p><p class="elsevierStylePara">Figure 2. Proposed protocol for the diagnosis and follow-up of acute renal failure/monoclonal gammopathy</p>" "pdfFichero" => "P1-E532-S3380-A11098-EN.pdf" "tienePdf" => true "multimedia" => array:2 [ 0 => array:8 [ "identificador" => "fig1" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11098_16025_25688_en_f1_11098.jpg" "Alto" => 1311 "Ancho" => 2089 "Tamanyo" => 1893534 ] ] "descripcion" => array:1 [ "en" => "Free light chains and the kidney" ] ] 1 => array:8 [ "identificador" => "fig2" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11098_16025_25689_en_f2_11098.jpg" "Alto" => 993 "Ancho" => 2083 "Tamanyo" => 1076778 ] ] "descripcion" => array:1 [ "en" => "Proposed protocol for the diagnosis and follow-up of acute renal failure/monoclonal gammopathy" ] ] ] "bibliografia" => array:2 [ "titulo" => "Bibliography" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:30 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Bradwell AR. Serum Free Light Chain Analysis (plus Hevylite). 6.ª ed. 2010." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47(4):673-80. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11274017" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Keren DF. Procedures for the evaluation of monoclonal immunoglobulins. Arch Pathol Lab Med 1999;123(2):126-32. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10050785" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Hutchison CA, Basnayake K, Cockwell P. Serum free light chain assessment in monoclonal gammopathy and kidney disease. Nat Rev Nephrol 2009;5(11):621-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19786994" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Katzmann JA. Screening panels for monoclonal gammopathies: time to change. Clin Biochem Rev 2009;30(3):105-11. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19841692" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48(9):1437-44. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12194920" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003;361(9356):489-91. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12583950" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al.\u{A0}International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23(2):215-24. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19020545" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "López-Corral L, García-Sanz R, San Miguel JF. [Value of serum free light chains assay in plasma cell disorders]. Med Clin (Barc) 2010;135(8):368-74." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Kyle RA, Durie BGM, Rajkumar SV, Landgren O, Blade J, Merlini G, et al.\u{A0}Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24(6):1121-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20410922" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Katzmann JA, Dispenzieri A, Kyle RA, Snyder MR, Plevak MF, Larson DR, et al.\u{A0}Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc 2006;81(12):1575-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17165636" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008;3(6):1684-90. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18945993" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Hutchison CA, Plant T, Drayson M, Cockwell P, Kountouri M, Basnayake K, et al.\u{A0}Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol 2008;9:11. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18808676" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Abadie JM, van Hoeven KH, Wells JM. Are renal reference intervals required when screening for plasma cell disorders with serum free light chains and serum protein electrophoresis? Am J Clin Pathol 2009;131(2):166-71. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19141376" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Bladé J, Fernández-Llama P, Bosch F, Montolíu J, Lens XM, Montoto S, et al.\u{A0}Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998;158(17):1889-93. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9759684" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J, et al.\u{A0}Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol 2007;18(3):886-95. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17229909" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Reyes GM, González IG, Alférez MJ, González JMM, Frutos MA. Cristales intracitoplasmáticos y síndrome de Fanconi en un paciente con mieloma IgA Kappa. Nefrologia 2001;XXI(2):213-6." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 17 => array:3 [ "identificador" => "bib18" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Herrera GA, Joseph L, Gu X, Hough A, Barlogie B. Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med 2004;128(8):875-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15270616" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 18 => array:3 [ "identificador" => "bib19" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Kariyawasan CC, Hughes DA, Jayatillake MM, Mehta AB. Multiple myeloma: causes and consequences of delay in diagnosis. QJM 2007;100(10):635-40. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17846059" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 19 => array:3 [ "identificador" => "bib20" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Basnayake K, Cheung CK, Sheaff M, Fuggle W, Kamel D, Nakoinz S, et al.\u{A0}Differential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney. J Clin Pathol 2010;63(10):884-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20876319" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 20 => array:3 [ "identificador" => "bib21" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Cockwell P, Hutchison CA. Management options for cast nephropathy in multiple myeloma. Curr Opin Nephrol Hypertens 2010;19(6):550-5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20827195" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 21 => array:3 [ "identificador" => "bib22" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Hutchison CA, Bridoux F. Renal impairment in multiple myeloma: time is of the essence. J Clin Oncol 2011;29(11):e312-313; author reply e314." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 22 => array:3 [ "identificador" => "bib23" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, et al.\u{A0}Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol 2011;22(6):1129-36. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21511832" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 23 => array:3 [ "identificador" => "bib24" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, et al.\u{A0}Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010;28(33):4976-84. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20956629" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 24 => array:3 [ "identificador" => "bib25" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ, et al.\u{A0}Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 2005;143(11):777-84. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16330788" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 25 => array:3 [ "identificador" => "bib26" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC, et al.\u{A0}Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 2008;73(11):1282-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18385667" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 26 => array:3 [ "identificador" => "bib27" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Ward RA. Protein-leaking membranes for hemodialysis: a new class of membranes in search of an application? J Am Soc Nephrol 2005;16(8):2421-30. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15975998" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 27 => array:3 [ "identificador" => "bib28" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Hutchison CA, Bradwell AR, Cook M, Basnayake K, Basu S, Harding S, et al.\u{A0}Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009;4(4):745-54. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19339414" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 28 => array:3 [ "identificador" => "bib29" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Martín-Reyes G, Toledo R, Torres A, et al. Tratamiento con hemodiálisis del fracaso renal agudo en el mieloma múltiple con filtros de alto poro.\u{A0} Nefrologia 2012;32(1):35-43." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 29 => array:3 [ "identificador" => "bib30" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Reyes GM, Valera A, Frutos MA, Ramos B, Ordónez V, Novales EL. Supervivencia de pacientes con mieloma tratados con diálisis. Nefrologia 2003;XXIII(2):131-6." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/20132514/0000003200000001/v0_201502091620/X2013251412000601/v0_201502091620/en/main.assets" "Apartado" => array:4 [ "identificador" => "35428" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Editorial Comments" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003200000001/v0_201502091620/X2013251412000601/v0_201502091620/en/P1-E532-S3380-A11098-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412000601?idApp=UINPBA000064" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 5 | 4 | 9 |
| 2024 October | 62 | 70 | 132 |
| 2024 September | 126 | 65 | 191 |
| 2024 August | 102 | 110 | 212 |
| 2024 July | 60 | 60 | 120 |
| 2024 June | 94 | 44 | 138 |
| 2024 May | 104 | 52 | 156 |
| 2024 April | 90 | 33 | 123 |
| 2024 March | 69 | 41 | 110 |
| 2024 February | 74 | 42 | 116 |
| 2024 January | 74 | 55 | 129 |
| 2023 December | 64 | 33 | 97 |
| 2023 November | 70 | 45 | 115 |
| 2023 October | 63 | 48 | 111 |
| 2023 September | 86 | 41 | 127 |
| 2023 August | 60 | 36 | 96 |
| 2023 July | 73 | 55 | 128 |
| 2023 June | 105 | 52 | 157 |
| 2023 May | 93 | 51 | 144 |
| 2023 April | 70 | 43 | 113 |
| 2023 March | 67 | 34 | 101 |
| 2023 February | 50 | 36 | 86 |
| 2023 January | 73 | 48 | 121 |
| 2022 December | 88 | 56 | 144 |
| 2022 November | 70 | 53 | 123 |
| 2022 October | 72 | 61 | 133 |
| 2022 September | 104 | 40 | 144 |
| 2022 August | 97 | 66 | 163 |
| 2022 July | 90 | 53 | 143 |
| 2022 June | 70 | 62 | 132 |
| 2022 May | 82 | 41 | 123 |
| 2022 April | 94 | 77 | 171 |
| 2022 March | 107 | 68 | 175 |
| 2022 February | 98 | 58 | 156 |
| 2022 January | 91 | 35 | 126 |
| 2021 December | 92 | 49 | 141 |
| 2021 November | 103 | 50 | 153 |
| 2021 October | 90 | 58 | 148 |
| 2021 September | 78 | 44 | 122 |
| 2021 August | 95 | 52 | 147 |
| 2021 July | 84 | 37 | 121 |
| 2021 June | 143 | 57 | 200 |
| 2021 May | 153 | 44 | 197 |
| 2021 April | 322 | 98 | 420 |
| 2021 March | 190 | 40 | 230 |
| 2021 February | 177 | 28 | 205 |
| 2021 January | 108 | 33 | 141 |
| 2020 December | 73 | 17 | 90 |
| 2020 November | 90 | 22 | 112 |
| 2020 October | 73 | 23 | 96 |
| 2020 September | 81 | 8 | 89 |
| 2020 August | 100 | 36 | 136 |
| 2020 July | 89 | 15 | 104 |
| 2020 June | 79 | 22 | 101 |
| 2020 May | 137 | 30 | 167 |
| 2020 April | 106 | 30 | 136 |
| 2020 March | 125 | 23 | 148 |
| 2020 February | 141 | 39 | 180 |
| 2020 January | 127 | 31 | 158 |
| 2019 December | 176 | 46 | 222 |
| 2019 November | 166 | 33 | 199 |
| 2019 October | 171 | 30 | 201 |
| 2019 September | 172 | 33 | 205 |
| 2019 August | 167 | 10 | 177 |
| 2019 July | 208 | 38 | 246 |
| 2019 June | 149 | 25 | 174 |
| 2019 May | 157 | 31 | 188 |
| 2019 April | 166 | 37 | 203 |
| 2019 March | 94 | 26 | 120 |
| 2019 February | 60 | 17 | 77 |
| 2019 January | 97 | 23 | 120 |
| 2018 December | 248 | 53 | 301 |
| 2018 November | 214 | 19 | 233 |
| 2018 October | 175 | 24 | 199 |
| 2018 September | 292 | 18 | 310 |
| 2018 August | 158 | 18 | 176 |
| 2018 July | 142 | 23 | 165 |
| 2018 June | 112 | 20 | 132 |
| 2018 May | 88 | 18 | 106 |
| 2018 April | 122 | 13 | 135 |
| 2018 March | 136 | 9 | 145 |
| 2018 February | 90 | 10 | 100 |
| 2018 January | 125 | 9 | 134 |
| 2017 December | 112 | 12 | 124 |
| 2017 November | 90 | 19 | 109 |
| 2017 October | 83 | 10 | 93 |
| 2017 September | 83 | 18 | 101 |
| 2017 August | 65 | 16 | 81 |
| 2017 July | 74 | 20 | 94 |
| 2017 June | 89 | 21 | 110 |
| 2017 May | 109 | 14 | 123 |
| 2017 April | 68 | 15 | 83 |
| 2017 March | 117 | 11 | 128 |
| 2017 February | 137 | 9 | 146 |
| 2017 January | 81 | 16 | 97 |
| 2016 December | 104 | 11 | 115 |
| 2016 November | 148 | 10 | 158 |
| 2016 October | 201 | 13 | 214 |
| 2016 September | 357 | 15 | 372 |
| 2016 August | 384 | 24 | 408 |
| 2016 July | 226 | 13 | 239 |
| 2016 June | 204 | 0 | 204 |
| 2016 May | 195 | 0 | 195 |
| 2016 April | 155 | 0 | 155 |
| 2016 March | 149 | 0 | 149 |
| 2016 February | 150 | 0 | 150 |
| 2016 January | 160 | 0 | 160 |
| 2015 December | 173 | 0 | 173 |
| 2015 November | 136 | 0 | 136 |
| 2015 October | 117 | 0 | 117 |
| 2015 September | 95 | 0 | 95 |
| 2015 August | 110 | 0 | 110 |
| 2015 July | 109 | 0 | 109 |
| 2015 June | 62 | 0 | 62 |
| 2015 May | 82 | 0 | 82 |
| 2015 April | 10 | 0 | 10 |
Show all
